ArticleBioinformatics advances2025
sc2DAT: workflow for targeting tumor subpopulations of single cells.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Summary: The rapid increase in volume, diversity, and quality of single-cell omics profiling opens new opportunities for drug and target discovery. While there are already many workflows developed for analysis and visualization of data collected with single-cell RNA-seq, few workflows output ranked drugs and targets specific for subpopulation of single cells. Here, we present the single cells to drugs and targets (sc2DAT) workflow, a web-based software application for predicting cell surface targets and therapeutic compounds tailored to target-specific cell types automatically identified from scRNA-seq and bulk RNA-seq datasets. sc2DAT can be used to develop hypotheses about selectively eliminating malignant subpopulation of cells in cancer, or reprogram disease tissues toward a healthier phenotype using compounds from the LINCS L1000 dataset. Such compounds are hypothesized to either reverse or mimic the direction of changes in gene expression signatures, restoring the subpopulation of cells towards a healthier phenotype. Availability and implementation: sc2DAT is available from: https://sc2dat.maayanlab.cloud; the source code is available from: https://github.com/MaayanLab/sc2DAT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.